S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

Satsuma Pharmaceuticals (STSA) Stock Forecast, Price & News

+0.22 (+6.88%)
(As of 05/27/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
55,238 shs
Average Volume
62,213 shs
Market Capitalization
$107.89 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive STSA News and Ratings via Email

Sign-up to receive the latest news and ratings for Satsuma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Satsuma Pharmaceuticals logo

About Satsuma Pharmaceuticals

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.


Satsuma Pharmaceuticals GAAP EPS of -$0.49
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Regional Banks
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$2.76 per share


Net Income
$-51.17 million
Pretax Margin




Free Float
Market Cap
$107.89 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.31 out of 5 stars

Medical Sector

261st out of 1,424 stocks

Pharmaceutical Preparations Industry

97th out of 681 stocks

Analyst Opinion: 3.3Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Satsuma Pharmaceuticals (NASDAQ:STSA) Frequently Asked Questions

Is Satsuma Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Satsuma Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Satsuma Pharmaceuticals stock.
View analyst ratings for Satsuma Pharmaceuticals
or view top-rated stocks.

Are investors shorting Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals saw a drop in short interest in May. As of May 15th, there was short interest totaling 381,200 shares, a drop of 27.9% from the April 30th total of 529,000 shares. Based on an average trading volume of 64,000 shares, the short-interest ratio is presently 6.0 days. Approximately 1.7% of the shares of the stock are sold short.
View Satsuma Pharmaceuticals' Short Interest

When is Satsuma Pharmaceuticals' next earnings date?

Satsuma Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Satsuma Pharmaceuticals

How were Satsuma Pharmaceuticals' earnings last quarter?

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) announced its earnings results on Tuesday, May, 10th. The financial services provider reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.01.
View Satsuma Pharmaceuticals' earnings history

What price target have analysts set for STSA?

3 brokerages have issued twelve-month price targets for Satsuma Pharmaceuticals' stock. Their forecasts range from $5.00 to $15.00. On average, they anticipate Satsuma Pharmaceuticals' stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 221.6% from the stock's current price.
View analysts' price targets for Satsuma Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Satsuma Pharmaceuticals' key executives?
Satsuma Pharmaceuticals' management team includes the following people:
  • Mr. John A. Kollins MBA, Pres, CEO & Director (Age 59, Pay $830k)
  • Mr. Thomas P. O'Neil, Chief Financial Officer (Age 57, Pay $550.08k)
  • Dr. Detlef F. Albrecht, Chief Medical Officer (Age 61, Pay $625.97k)
  • Mr. Mic Iwashima, VP & Head of Operations (Age 44)
  • Mr. Robert Schultz, VP & Head of CMC (Age 57)
  • Dr. Shannon Strom Ph.D., VP & Head of Regulatory Affairs (Age 46)
  • Mr. Robert M. Janosky, Chief Commercial Officer
What other stocks do shareholders of Satsuma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Satsuma Pharmaceuticals investors own include Verrica Pharmaceuticals (VRCA), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Dynavax Technologies (DVAX), Homology Medicines (FIXX), Gilead Sciences (GILD), Novan (NOVN), Pfizer (PFE) and Akebia Therapeutics (AKBA).

When did Satsuma Pharmaceuticals IPO?

(STSA) raised $75 million in an initial public offering on Friday, September 13th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Credit Suisse, SVB Leerink and Evercore acted as the underwriters for the IPO.

What is Satsuma Pharmaceuticals' stock symbol?

Satsuma Pharmaceuticals trades on the NASDAQ under the ticker symbol "STSA."

Who are Satsuma Pharmaceuticals' major shareholders?

Satsuma Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.05%), Ghost Tree Capital LLC (1.50%), Walleye Capital LLC (0.83%), Walleye Capital LLC (0.83%), Dimensional Fund Advisors LP (0.70%) and BlackRock Inc. (0.43%). Company insiders that own Satsuma Pharmaceuticals stock include Commodore Capital Lp, Detlef Albrecht and Thomas P O'neil.
View institutional ownership trends for Satsuma Pharmaceuticals

Which institutional investors are selling Satsuma Pharmaceuticals stock?

STSA stock was sold by a variety of institutional investors in the last quarter, including Ghost Tree Capital LLC, BlackRock Inc., Vanguard Group Inc., and Simplex Trading LLC.
View insider buying and selling activity for Satsuma Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Satsuma Pharmaceuticals stock?

STSA stock was bought by a variety of institutional investors in the last quarter, including Walleye Capital LLC, Walleye Capital LLC, Dimensional Fund Advisors LP, and State Street Corp.
View insider buying and selling activity for Satsuma Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Satsuma Pharmaceuticals?

Shares of STSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Satsuma Pharmaceuticals' stock price today?

One share of STSA stock can currently be purchased for approximately $3.42.

How much money does Satsuma Pharmaceuticals make?

Satsuma Pharmaceuticals has a market capitalization of $107.89 million. The financial services provider earns $-51.17 million in net income (profit) each year or ($1.78) on an earnings per share basis.

How many employees does Satsuma Pharmaceuticals have?

Satsuma Pharmaceuticals employs 21 workers across the globe.

When was Satsuma Pharmaceuticals founded?

Satsuma Pharmaceuticals was founded in 2016.

What is Satsuma Pharmaceuticals' official website?

The official website for Satsuma Pharmaceuticals is www.satsumarx.com.

How can I contact Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals' mailing address is 400 OYSTER POINT BOULEVARD SUITE 221, SOUTH SAN FRANCISCO CA, 64080. The financial services provider can be reached via phone at 650-410-3200.

This page was last updated on 5/28/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.